IPM Take
This article should be framed around the gap, not the brand. In first-line metastatic triple-negative breast cancer, immunotherapy has changed care for some patients, but not for everyone. Datopotamab deruxtecan is relevant because it targets the group left outside that route: patients for whom PD-1 or PD-L1 inhibitors are not an option. The access challenge is to make that eligibility visible and to avoid confusion in a fast-moving ADC field.
Executive Summary
TROPION-Breast02 evaluated datopotamab deruxtecan against investigator’s choice chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer who were not candidates for PD-1 or PD-L1 inhibitor therapy. The peer-reviewed trial publication reported significant improvements in progression-free survival and overall survival versus chemotherapy. ASCO-linked reporting of the primary results described TROPION-Breast02 as meeting both dual primary endpoints and supporting a new first-line treatment option for this immunotherapy-ineligible population.
Why it matters
- Clinicians: Need to define where ADCs fit for patients who are not candidates for immunotherapy.
- HTA bodies / payers: Must assess value in a clinically defined subgroup rather than the whole mTNBC population.
- Patients / advocates: Should watch whether access criteria are clear, timely and fair for patients with limited first-line options.
Triple-negative breast cancer is often discussed as one disease, but treatment access is increasingly divided by eligibility. Some patients can receive immunotherapy-based regimens. Others cannot. That second group is where the unmet need remains particularly sharp.
TROPION-Breast02 matters because it targets that gap. Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate, a class designed to deliver cytotoxic therapy more selectively to tumour cells. In this trial, the comparison was not theoretical. It was against chemotherapy in a first-line population without an immunotherapy option.
The policy point is straightforward: ADCs are expanding, but their use will not be simple. Pathways will need to account for PD-L1 or immunotherapy eligibility, prior therapy, toxicity management, patient preference and treatment availability. A therapy can be clinically relevant and still hard to place if the pathway is poorly defined.
For IPM, the access issue is eligibility precision. Triple-negative breast cancer patients should not lose time because the system cannot decide which first-line route applies to them.
